{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"After Cy8: <1 hour (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"After Cy8: ≥1 to <2 hours (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}],"title":"After Cy8: ≥2 to <3 hours (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"After Cy8: ≥3 to <4 hours (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"After Cy8: ≥4 hours (n=166)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"After Cy15: <1 hour (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}],"title":"After Cy15: ≥1 to <2 hours (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}],"title":"After Cy15: ≥2 to <3 hours (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"After Cy15: ≥3 to <4 hours (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"}]}],"title":"After Cy15: ≥4 hours (n=130)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}],"title":"After Cy20: <1 hour (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32"}]}],"title":"After Cy20: ≥1 to <2 hours (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"21"}]}],"title":"After Cy20: ≥2 to <3 hours (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"13"}]}],"title":"After Cy20: ≥3 to <4 hours (n=126)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19"}]}],"title":"After Cy20: ≥4 hours (n=126)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"}],"units":"Participants"}],"description":"All investigator physicians and nurses involved in this study were asked to provide the staff time that could be saved with each administration of rituximab SC as compared with rituximab IV to participants in routine practice afetr Cy 8, 15, 20 and categorized as less than (\\<) 1 hr, at least 1 hr but \\<2 hrs, at least 2 hrs but \\<3 hrs, at least 3 hrs but \\<4 hrs, \\>/=4 hrs. Staff were asked not to consider the time needed for the first IV administration. Analysis was done in all participants to show a comparison on the time saved by staffs when administered via SC and IV.","groups":[{"description":"Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP): First cycle rituximab IV infusion (375 mg/m\\^2) + 7 cycles of rituximab SC 1400 mg in combination with up to 8 cycles of CHOP or CVP chemotherapy administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months. Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP): Eight cycles of rituximab IV infusion (375 mg/m\\^2; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\\^2) once every 8 weeks for 24 months.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"ITT Population. Here, number of participants analyzed = participants evaluable for the outcome measure. Here \"n\" = number of participants evaluable for this outcome measure at specified timepoint.","reportingStatus":"POSTED","timeFrame":"After Cycle 8 of induction treatment (24 weeks) and during the maintenance part of the study after 12 months (i.e., Cycle 15), and after the end of the maintenance treatment, (i.e., Cycle 20) (1 Cycle=4 weeks for Cycle 8 and 8 weeks for Cycles 15 and 20)","title":"Stage I and II (Pooled): Percentage of Responses Showing Time Saved of Staff as Per Physician/Nurse Opinions With Each Administration of Rituximab SC as Compared to Rituximab IV at the End of Cy 8, 15 and 20","type":"SECONDARY","unitOfMeasure":"percentage of responses"}